Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Three-year Overall Survival For Patients With Advanced Melanoma Treated With Pembrolizumab In KEYNOTE-001.

C. Robert, A. Ribas, O. Hamid, A. Daud, J. Wolchok, A. Joshua, W. Hwu, J. Weber, Tara C. Gangadhar, Richard W. Joseph, R. Dronca, A. Patnaik, H. Zarour, R. Kefford, P. Hersey, X. Li, Scott J. Diede, S. Ebbinghaus, F. S. Hodi
Published 2016 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
9503Background: The anti–PD-1 antibody pembro (pembro; MK-3475) prevents PD-1 from binding to its ligands, PD-L1 and PD-L2, and is approved for treating advanced melanoma at a dose of 2 mg/kg every 3 wk (Q3W). Pembro demonstrated superior PFS over chemotherapy for ipilimumab (ipi)-refractory melanoma (KEYNOTE-002) and superior OS and PFS over ipi for advanced melanoma (KEYNOTE-006). We present 3-year OS data for all patients (pts) with melanoma enrolled in the phase 1b KEYNOTE-001 study (NCT01295827). Methods: Pts were enrolled in ipi-naive and ipi-treated cohorts and received pembro 2 or 10 mg/kg Q3W or 10 mg/kg Q2W until intolerable toxicity, progression, or investigator decision. Clinically stable pts with radiographic progression could remain on pembro until progression was confirmed. Response was assessed by RECIST v1.1 every 12 wk. After pembro discontinuation, pts were contacted to assess survival every 3 mo. OS was estimated using the Kaplan-Meier method. Results: Of the 655 pts enrolled, 24% had ...



This paper is referenced by
10.12788/JCSO.0336
Meeting the potential of immunotherapy: new targets provide rational combinations
J. D. Lartigue (2017)
10.1007/s00262-017-1954-6
PD-1 and PD-L1 antibodies in cancer: current status and future directions
A. Balar (2017)
10.15406/mojtr.2018.01.00034
Prolonged survival of the patient with metastatic melanoma sequentially treated with different therapeutics
Samoylenko (2018)
10.1007/s40257-017-0325-6
Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives
E. A. Rozeman (2017)
10.1001/jamaoncol.2016.3418
Recent Developments in Melanoma Therapy.
A. Menzies (2016)
10.1177/0300891619868009
Developing a score system to predict therapeutic outcomes to anti-PD-1 immunotherapy in metastatic melanoma
A. Indini (2019)
10.1055/S-0044-100836
Systemtherapie des fortgeschrittenen metastasierten Melanoms
J. Kleemann (2018)
10.1080/14712598.2017.1378640
Immunotherapy in managing metastatic melanoma: which treatment when?
T. Amaral (2017)
10.2147/CMAR.S92546
Challenging the standard of care in advanced melanoma: focus on pembrolizumab
Raghad M Abdul-Karim (2017)
10.1080/2162402X.2016.1234572
Responses to immune checkpoint inhibitors in nonagenarians
R. Johnpulle (2016)
10.1093/jnci/djx063
A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non–Small Cell Lung Cancer
D. Goldstein (2017)
10.17116/ONKOLOG20176574-80
Immuno-oncology: new possibilities of drug therapy for solid tumors
L. Bolotina (2017)
10.1186/s13045-017-0458-3
The use of immunotherapy in the treatment of melanoma
Tala Achkar (2017)
10.1080/14712598.2017.1309388
Pembrolizumab use for the treatment of advanced melanoma
P. Specenier (2017)
10.1097/CMR.0000000000000336
The cessation of anti-PD-1 antibodies of complete responders in metastatic melanoma
R. Ladwa (2017)
10.1186/s12967-017-1278-5
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
P. Ascierto (2017)
10.1016/j.ejca.2017.07.022
Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.
O. Hamid (2017)
10.1038/bjc.2016.321
Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series
M. Carlino (2016)
10.1097/CJI.0000000000000186
Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program
Tara C. Gangadhar (2017)
10.1007/s00432-019-02839-w
Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions
M. Gallo (2019)
10.1016/J.ONCOHP.2016.07.001
Nouveaux médicaments contre les cancers pédiatriques : ce qui doit bouger en Europe
G. Vassal (2016)
10.1016/S0140-6736(17)31601-X
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
J. Schachter (2017)
10.1016/j.semradonc.2017.03.002
Radiation and Immune Checkpoint Blockade: From Bench to Clinic.
J. Shabason (2017)
10.1097/PPO.0000000000000245
Targeted Therapies in Combination With Immune Therapies for the Treatment of Metastatic Melanoma
S. A. Christiansen (2017)
10.1097/CJI.0000000000000204
Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices
C. Cowey (2018)
Resistance to PD 1 / PDL 1 checkpoint inhibition
J. S. O’Donnell (2016)
10.18632/oncotarget.18641
Isolation and detection of circulating tumour cells from metastatic melanoma patients using a slanted spiral microfluidic device.
C. Aya-Bonilla (2017)
10.1016/S1470-2045(16)30409-0
Ipilimumab plus nivolumab for advanced melanoma.
J. Hassel (2016)
10.1093/annonc/mdx076
Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic
S. P. Kang (2017)
10.1007/s00117-017-0281-4
[Malignant melanoma : Current status].
J. Winkler (2017)
10.1136/bcr-2016-218308
Risk of cumulative toxicity after complete melanoma response with pembrolizumab
A. Hsieh (2017)
10.1097/MD.0000000000016417
Prediction of response to immune checkpoint inhibitor therapy using 18F-FDG PET/CT in patients with melanoma
K. Amrane (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar